首页 正文

Real-world effectiveness of lorlatinib in previously treated ROS1 positive NSCLC patients in Taiwan

{{output}}
Background: Lorlatinib is a novel ATP-competitive macrocyclic tyrosine kinase inhibitor (TKI) that targets both anaplastic lymphoma kinase (ALK) and the ROS proto-oncogene 1 (ROS1) rearrangement. ROS1 is a key driver gene found i... ...